NCT02912104View on ClinicalTrials.gov

A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

January 5, 2022

Study Completion Date

January 5, 2023

Conditions
Primary Ovarian InsufficiencyPremature Ovarian FailureInfertility
Interventions
BIOLOGICAL

human amniotic epithelial cells (hAECs) transplantation

hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.

Trial Locations (1)

200030

The International Peace Maternity and Child Health Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

INDUSTRY

lead

International Peace Maternity and Child Health Hospital

OTHER

NCT02912104 - A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure | Biotech Hunter | Biotech Hunter